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Background: Controversy is ongoing about whether a minority mutant present at frequencies 
below 15% may be clinically relevant and should be considered to guide treatment.
Methods: Resistance-associated substitution (RAS) studies were performed in patients before 
and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequenc-
ing (NGS).
Results: We have found two patients with genotype 1a infection having RAS in 3.5%–7.1% of 
the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Co-
selection of RAS located in a region not directly affected by the antiviral treatment also occurred. 
This observation calls into question, the recommendations to guide RAS-based direct-acting 
antiviral (DAA) treatment only when RAS are present in >15% of the sequences generated.
Conclusion: Our results suggests that RAS study should include all three HCV DAA target 
proteins and minority mutants should be considered as clinically relevant.
Keywords: HCV, minority mutants, NGS, antiviral resistance
Introduction
Although new-generation direct-acting antivirals (DAAs) are effective for treating 
hepatitis C virus (HCV) infection, 5%–10% of patients fail the treatment because 
of resistance-associated substitutions (RAS).1 Controversy is ongoing about whether 
anti-HCV treatment should be guided by RAS detection (reviewed in the study by 
Pérez et al2). International guidelines recommend that physicians with access to reli-
able tests (population or deep sequencing) assessing HCV resistance to NS5A inhibi-
tors should use this information to guide treatment. However, only RAS present in 
>15% of sequences are considered clinically significant.3,4 In our center, RAS study 
based on massively parallel, next-generation sequencing (NGS) using the MiSeq 
platform is included in routine HCV management with DAA-based treatment. We 
systematically study the three HCV target genes – NS3, NS5A, and NS5B. Here, we 
report on two HCV G1a-infected patients failing treatment with Ledipasvir[NS5Ai]+ 
Sofosbuvir[NS5Bi]) associated with mutants present at much less than 15% of the 
viral quasispecies at baseline.
Patients and methods
Patients
This study includes two patients both infected with G1a subtype: patient 1, a treatment-
naïve man – with HCV–HIV coinfection (HIV–RNA <40 copies/mL at initiation of 
anti-HCV therapy), fibrosis F2 (7.8 kpa) measured by noninvasive liver elastography 
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(Fibroscan), and viral load 2.19×106 IU/mL – was treated with 
LDV + SOF for 8 weeks. Adherence, estimated by patient’s 
report and pill count at the hospital pharmacy together with 
viral decline at weeks 4 and 8, was good. HCV–RNA was 
undetectable at the end of treatment. During follow-up, a 
viral load of 5.89×103 IU/mL was detected 19 weeks after 
stopping LDV + SOF. Patient 2, a treatment-naïve man – with 
chronic HCV infection, fibrosis F3 (10.5 kpa) measured by 
Fibroscan, and viral load 1.04×107 IU/mL– was treated with 
LDV + SOF for 12 weeks. Adherence to treatment was good, 
and HCV DNA was undetectable at 8 weeks and at treatment 
completion. During follow-up, a viral load of 1.30×107 IU/mL 
was detected 12 weeks after stopping LDV + SOF treatment.
The risk factor for HCV acquisition for patient 1 was 
injecting drug use in the 1980. Since then, the patient has 
not taken any drugs. For patient 2, after continuous deep 
interviewing, we were unable to identify any risk factor for 
HCV infection.
Two serum samples of each patient, at baseline and during 
treatment failure time, were analyzed. Briefly, HCV–RNA was 
extracted either manually from 140 µL of serum using the 
QIAamp Viral RNA Mini Kit (Qiagen NV, Venlo, the Neth-
erlands) or automatically using a total nucleic acid isolation 
kit in a COBAS/AmpliPrep system (Hoffman-La Roche Ltd., 
Basel, Switzerland) following the manufacturers’ instruc-
tions. Standard measures to avoid contamination were strictly 
enforced.5 A high-resolution HCV subtyping method was used 
with samples before and after treatment failure to conclusively 
identify HCV subtype and to determine whether there was 
more than one subtype at relapse.6 Besides, a phylogenetic 
analysis at the NS5B region was performed to discard reinfec-
tion. The three DAA–HCV targeted regions (NS3, NS5A, and 
NS5B) were amplified by RT-PCR-nested and deep sequenced 
using MiSeq (Illumina, San Diego, CA, USA) platform. The 
raw data generated by MiSeq in 2×300 mode were analyzed 
using in-house R scripts7 to obtain the final RAS reports.
RT-PCR-nested HCV amplification
Reverse transcription and PCR (RT-PCR) were performed 
using the OneStep RT-PCR Transcriptor kit (Roche Applied 
Science, Basel, Switzerland). Subtype-specific primers were 
used to amplify the NS3, NS5A, and NS5B regions (primer 
sequences are not provided, as they are under patent study). 
A second internal or nested PCR amplifying a shorter frag-
ment was performed to obtain sufficient DNA product for 
sequencing. This nested PCR used the FastStart High Fidel-
ity PCR system, dNTPack (Roche Applied Science), with a 
previously described protocol.56
Amplification products were analyzed by electrophoresis 
on 2% agarose gel. Negative controls (amplification in the 
absence of RNA) were included in all amplification runs to 
ensure absence of contamination. Size-specific expected 
bands were purified from agarose gel (Agarose MP, Roche 
Indianapolis, IN, USA) using the QIAquick Gel Extrac-
tion Kit (Qiagen, Valencia, CA, USA) and quantified using 
Nanodrop (Thermo Fisher Scientific, Waltham, MA, USA).
Deep sequencing
Nested-PCR products were purified from agarose gel bands 
(QIAquick Gel Extraction Kit, Qiagen), quantified (QubitTM 
dsDNA BR Assay Kit, Thermo Fisher Scientific), and tested 
for quality (Bioanalyzer DNA 1000, Agilent Technologies, 
Santa Clara, CA, USA). PCR products from a single patient 
were pooled at a normalized concentration and purified 
(Agentcourt® AM0050ure® XP, Beckman Coulter, Brea, CA, 
USA). Another normalization was performed to 1.5 ng/µL, 
followed by the library preparation protocol using the Kapa 
Hyper Prep Kit (Roche Applied Science, Pleasanton, CA, 
USA) and the SeqCap Adapter Kit A/B (24 Index Nimblegen, 
Roche Pleasanton, CA, USA) for the pool indexing. A second 
cleanup was performed (Kapa Pure Beads, KapaBiosystems, 
Roche, Pleasanton, CA, USA) and a quality control assay 
was done using the Bioanalyzer. Each pool was normalized 
to 4 nM, and appropriated volumes of each pool were added 
to the final library, which was quantified by LightCycler480 
(Kapa Library Quantification Kit, KapaBiosystems). Last 
dilution of the library was prepared and mixed with an inter-
nal DNA control (PhiX control V3, Illumina) before being 
sequenced using the MiSeq platform with MiSeq Reagent 
Kit V3 (Illumina).
Ultra deep sequencing data management
We have developed a bioinformatic haplotype-centric proce-
dure to exclude full reads that do not meet minimum quality 
requirements. Once acquiring raw data from MiSeq (fastq), 
the first step included the overlap of paired-end reads using 
FLASH. The FLASH parameters were established as a mini-
mum overlap between R1 and R2 of 20 bp with a maximum 
of 10% differences. Reads not fulfilling this requirement 
were discarded. The yield of this process ranged from 60% 
to 80% in all our experiments. The quality profile of the 
overlapped reads was substantially better than the original 
reads, with a 5% lower quantile consistently above Q30, 
and just slightly below Q30 for the ~50 bp in the center. A 
filter step on the FLASH reads was added to improve both 
sensitivity and specificity, the threshold was established by 
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experiments with spikes and controls, finally excluding all 
reads with more than 5% bp with Phred score below Q30. 
The yield of this filter is very sensitive to the general qual-
ity of the sequencing run and has been found to be in the 
range of 70%–90%. The third step was demultiplexing by 
specific primers to obtain a fasta file by region. Reads were 
then collapsed into haplotypes with corresponding frequen-
cies. Haplotypes were aligned with the reference sequence, 
and haplotypes containing more than two indeterminations, 
three gaps, or 99 differences were also discarded. Accepted 
indeterminations and gaps were repaired as per the contents of 
the dominant haplotype. The yield of this process was above 
90% in all cases. Then, reads were translated to amino acids, 
and the intersection between forward and reverse haplotypes 
with abundances not below 0.2% was performed. The yield 
of this process has been found in the range 45%–60%. Based 
on the controls, all amino acid variants by site or haplotype 
at 1% or above are reported. The global yield is 15%–30% 
of raw reads.
Results and discussion
Between 21,000 and 114,000 reads/sample were obtained 
(Table 1). At baseline in patient 1, the S122G substitution in 
NS3 and E62D in NS5A was present in 7.1% and 3.7% of the 
viral population, respectively. At failure, the two substitutions 
were present in 100% of the sequences. According to Inter-
national guidelines,4 E62D substitution confers resistance 
to NS5A inhibitors in G1b patients. Although this effect has 
not been reported for G1a, this substitution may explain the 
treatment failure.
At baseline in patient 2, the Q80L and R155K substitution 
in NS3 and Y93H in NS5A were present at 6.5%, 4.8%, and 
3.5%, respectively. At failure, NS3 and NS5A were observed 
in 100% of the sequences obtained from this sample. More-
over, the Y93H NS5A substitution was found in combination 
with the L31I RAS (not detected at baseline) in 99.5% of 
genomes. Both Y93H and L31I confer resistance to ledipasvir 
in HCV G1a patients. NS5B mutations were not observed in 
either patient (Table 1).
These observations suggest that minority RAS pres-
ent at much lower than 15%, which may go unnoticed 
in population sequencing, may be relevant for treatment 
planning. Clinically relevant mutants have long been known 
to be present as minority components of replicating viral 
populations.8 Implication of preexisting minority viral 
variants and its implication on drug treatment failure needs 
further studies.9–13 Specifically, our results support reports 
that baseline RAS using a 1% cutoff resulted in lower SVR 
rates than the rates in patients showing no RAS.1 Actually, 
there is no theoretical or experimental rationale other than 
the limit of detection of population sequencing to use the 
15% cutoff.
Of note, NS3 RAS were also observed at failure, even 
though antiviral treatment was directed against NS5A and 
NS5B. NS3 RAS could not have been specifically selected 
by the drug regimen. In this scenario, three alternative or 
concomitant explanations are possible. First of all, the 
phenomenon can be caused by a random event in which 
the NS3 RAS mutation appeared and gave advantage to 
the viral genome (improve fitness). Second, because of 
a mutation in NS5A is compensated with a mutation in 
NS3, both proteins interact with the replication complex. 
Third, by the phenomenon of hitchhiking, in which the 
genome carrying the resistance mutation (RAS to NS5A) is 
selected and dominates the viral population. This selection 
sweep can produce the hitchhiking of mutations, such as 
resistance mutations to other antiviral targets such as NS3 
that accompany the selected mutation in the same genome. 
Anyway, this result suggests that contrary to international 
guidelines recommendation RAS study should always 
Table 1 Frequency of Ras detected at baseline and at failure after lDV + sOF treatment. Reads refer to the number of sequences 
analyzed by next-generation sequencing (Miseq platform)
Patient Coding 
region
Basal Ledipasvir + sofosbuvir failure
Substitution Percentage Reads Substitution Percentage Reads
1 ns3 s122g 7.1 81,916 s122g 100 99,522
ns5a e62D 3.7 69,732 e62D 100 114,584
ns5B no Ras no Ras 90,083 no Ras no Ras 56,386
2 ns3 R155K 4.8 18,898 R155K 100% 64,929
s122g 11.4 18,898
Q80l 6.5 18,898 Q80l 100% 64,929
ns5a Y93h 3.5 21,272 Y93h 99.6% 68,830
l31I 99.5% 68,830
ns5B no Ras no Ras 21,839 no Ras no Ras 77,164
Abbreviations: lDV, ledipasvir; Ras, resistance-associated substitutions; sOF, sofosbuvir.
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include the three target regions (NS3, NS5A, and NS5B) 
independently of the treatment and consider RAS muta-
tions at frequencies of around 1%, not being so useful 
population sequencing.
In contrast to recommendations in international guide-
lines, our results suggest that RAS mutations at <15% may be 
clinically relevant and should be taken into consideration in 
treatment decisions. Detailed information on substitutions in 
all three DAA target regions (NS3, NS5A, and NS5B) should 
be provided by NGS, regardless of the failed treatment, in 
order to design the most suitable salvage therapy.
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